Telemedicine maturity by service lines: Which specialties are more advanced?

While telemedicine is growing in popularity and availability, some specialties have been more in-demand for virtual consultations than others.

Advertisement

Telemedicine provider REACH Health conducted its 2015 U.S. Telemedicine Industry Benchmark Survey in November and December 2014, collecting and analyzing the responses of approximately 230 healthcare professionals regarding the state of telemedicine in their organizations.

Survey results indicated certain service lines tend to have more mature telemedicine programs than others. The survey delineated maturity of telemedicine programs by those that have been established for more than three years versus fewer than three years.

Here are the most mature service lines (i.e. Those that have been established for more than three years):

1. Stroke: 34 percent

2. Radiology: 27 percent

3. Neurology: 23 percent

4. Psychiatry/behavioral health: 18 percent

5. ICU: 16 percent

Here are the least mature service lines (i.e. The service lines with the fewest programs having been established for more than three years):

1. Dentistry: <1 percent

2. Rehab/therapy: 2 percent

3. Orthopedics: 3 percent

4. Pulmonology: 5 percent

4. Infectious disease management: 5 percent

4. Obstetrics/perinatology: 5 percent

4. Surgical follow-ups: 5 percent

More articles on telemedicine:

Teladoc to file for IPO: 5 things to know
Anthem expands telemedicine offerings in Connecticut
Gritman Medical Center launches telemedicine program

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.